Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround

Zacks Dec 13 08:40 ET

Reported Earlier, Lyell Releases IMPT-314 Phase 1-2 Results, Highlighting Efficacy And Manageable Safety In B-Cell Lymphoma Treatment At ASH 2024

BenzingaDec 10 01:58 ET

Lyell Immunopharma Announces Promising Initial Clinical Data for IMPT-314 in Treatment of CAR T-Naïve Patients With Large B-Cell Lymphoma

Quiver QuantitativeDec 9 21:10 ET

Express News | Lyell Immunopharma Inc - Impt-314 Receives Fast Track Designation From FDA

ReutersDec 9 21:01 ET

Lyell Presents Positive Initial Clinical Data From the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

GlobeNewswireDec 9 21:00 ET

Express News | Lyell Presents Positive Initial Clinical Data From the Phase 1-2 Clinical Trial of Impt-314 for the Treatment of B-Cell Lymphoma at the 2024 Ash Annual Meeting

ReutersDec 9 21:00 ET